(APRE)
NCM – Real Time Price. Currency in USD
0.68
-0.02 (-2.43%)
At close: Mar 27, 2026, 4:00 PM EDT
0.66
-0.02 (-3.44%)
After-hours: Mar 27, 2026, 7:54 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.68
-0.02 (-2.43%)
At close: Mar 27, 2026, 4:00 PM EDT
0.66
-0.02 (-3.44%)
After-hours: Mar 27, 2026, 7:54 PM EDT
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
| Name | Position |
|---|---|
| Dr. Eugene P. Kennedy F.A.C.S., M.D. | Chief Medical Advisor |
| Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer |
| Dr. Michel Afargan Ph.D. | Head of Pharmacology Development |
| Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director |
| Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy |
| Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor |
| Ms. Andrea Epstein | Controller |
| Date | Type | Document |
|---|---|---|
| 2026-03-16 | S-8 | tm268514d1_s8.htm |
| 2026-01-29 | 8-K | tm264417d1_8k.htm |
| 2026-01-23 | 8-K | tm263963d1_8k.htm |
| 2026-01-09 | 8-K | apre-20260109x8k.htm |
| 2025-12-29 | D | |
| 2025-12-19 | S-3 | tm2533811-1_s3.htm |
| 2025-12-09 | 8-K | tm2533057d1_8k.htm |
| 2025-12-08 | S-8 | tm2532817d1_s8.htm |
| 2025-11-12 | 8-K | apre-20251112x8k.htm |
| 2025-10-24 | 8-K | apre-20251024x8k.htm |